William N Bichai MD INC
William N Bichai MD INC was paid $3.80M by Medicaid between Jan 2018 and Dec 2024, across 67 billing codes. Its largest line is 99215, doctor's office visit, returning patient (complex) — 29% of everything it billed.
33Billing provider infoWILLIAM N BICHAI MD INC
BAKERSFIELD, CA 93301
BAKERSFIELD, CA 93301
33aNPI1720316144assigned 11/23/2009
33bProvider typeSpecialist
28Total paid$3.80M
24GClaims92,972
24DCodes billed67
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in California
Rank by total paid#65 of 1,230
Median peer was paid$51K
This provider vs. median74×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,858 | $221K | |
| 2019 | 7,464 | $163K | |
| 2020 | 9,221 | $328K | |
| 2021 | 15,457 | $594K | |
| 2022 | 16,833 | $715K | |
| 2023 | 16,517 | $554K | |
| 2024incomplete | 18,622 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 29% | 16,562 | 15,708 | $1.10M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 12,931 | 12,068 | $528K |
| 99205 | Prolong outpt/office vis | 7.2% | 2,365 | 2,354 | $274K |
| 99223 | Prolong inpt eval add15 m | 7.1% | 3,116 | 3,047 | $269K |
| 99308 | Subsequent nursing facility care, per day, straightforward | 6.3% | 12,082 | 6,606 | $241K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 5.4% | 4,413 | 1,624 | $205K |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | 5.2% | 1,341 | 1,339 | $199K |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | 2.7% | 744 | 743 | $104K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 2.0% | 1,985 | 841 | $78K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 2.0% | 12,549 | 12,065 | $78K |
| G9008 | Coordinated care fee, physician coordinated care oversight services | 1.9% | 1,062 | 925 | $71K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 1.7% | 220 | 218 | $65K |
55 more codes
| 99306 | Prolong nursin fac eval 15m | 1.6% | 1,026 | $59K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 854 | $36K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 125 | $35K |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 2,314 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,481 | $32K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 559 | $29K |
| 99316 | <1% | 602 | $25K | |
| 90686 | <1% | 739 | $22K | |
| 99336 | <1% | 826 | $21K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 1,072 | $21K |
| 0011A | <1% | 494 | $20K | |
| G9012 | Other specified case management service not elsewhere classified | <1% | 342 | $18K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 57 | $18K |
| 82607 | <1% | 1,349 | $17K | |
| 99348 | <1% | 1,157 | $17K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 711 | $16K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 143 | $16K |
| 0012A | <1% | 346 | $13K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 261 | $13K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 369 | $12K |
| 0001A | <1% | 273 | $11K | |
| 0002A | <1% | 262 | $10K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 616 | $9K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 197 | $9K |
| 90656 | <1% | 319 | $8K | |
| 0003A | <1% | 220 | $8K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 67 | $8K |
| 90682 | <1% | 129 | $8K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 40 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 115 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 669 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 213 | $4K |
| 0013A | <1% | 84 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 27 | $3K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 54 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 294 | $2K |
| 99386 | <1% | 17 | $2K | |
| 90694 | <1% | 18 | $1K | |
| 93000 | <1% | 40 | $1K | |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | <1% | 31 | $771.40 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15 | $769.65 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 47 | $674.54 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 88 | $527.03 |
| 0004A | <1% | 17 | $500.00 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 15 | $288.82 |
| G9920 | Screening performed and negative | <1% | 1,553 | $196.86 |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 128 | $7.15 |
| 3078F | 0% | 39 | $0.00 | |
| 91300 | 0% | 15 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 32 | $0.00 |
| 3075F | 0% | 14 | $0.00 | |
| 3074F | 0% | 52 | $0.00 | |
| 3044F | 0% | 45 | $0.00 | |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 14 | $0.00 |
| 3079F | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBICHAI, WILLIAM (PROVIDER/OWNER)